Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Bookmark and Share   

Home

Marketplace
Database
Deals
News
Store
Resources
Contact Us

 

 

 

News

 

Venture Capital Database 2014 Now Available

Loxo Oncology Closes a $24 Million Series B Financing and Expands Management Team

-- Proceeds to advance company’s lead clinical product and expand pipeline --

STAMFORD, Conn., May 6, 2014-- Loxo Oncology, Inc., a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, announced today that it has closed a $24 million Series B private financing round led by New Enterprise Associates (NEA). Existing investors Aisling Capital and OrbiMed Advisors LLC also participated in the round. The company also announced the appointment of Mikel Moyer, PhD, as chief scientific officer.

“The Loxo Oncology team is rapidly progressing towards our goal of bringing targeted therapies to patients with genetically defined cancers,” said Josh Bilenker, MD, chief executive officer. “With the proceeds from this financing, we are now in an even stronger position to advance our lead asset LOXO-101, currently in a Phase 1 dose escalation trial, and to expand our exciting discovery pipeline.”

“In just ten months since it began operations, Loxo Oncology has successfully initiated a clinical trial for the lead TRK program, made substantial progress on its discovery pipeline and assembled an outstanding management team and scientific advisory board,” said Dr. M. James Barrett, General Partner, NEA. “We believe Loxo Oncology has a tremendous opportunity to contribute important targeted therapies to the field of oncology, and we are pleased to support the company’s continued growth with this financing.”

In conjunction with the financing, Dr. Barrett will join Loxo Oncology’s board of directors. Sara Nayeem, MD, a principal at NEA, will also join the board as an observer.

Dr. Moyer was most recently the vice president of molecular discovery at Epizyme, where he led the discovery and optimization of histone methyltransferase inhibitor drug candidates, two of which are currently in clinical development (EPZ-5676 and EPZ-6438). Dr. Moyer’s career in discovery and pre-clinical development has also included leadership roles at The Broad Institute of MIT and Harvard and at Pfizer.

About Loxo Oncology

Loxo Oncology was incorporated in Delaware in May 2013 and was founded by Josh Bilenker, MD. Loxo Oncology is committed to rapidly bringing to the clinic targeted cancer therapies that have an opportunity for clinical success in genetically defined patient populations. Loxo Oncology derives its company name from an attendant of the Greek goddess Artemis, who represented the concept of trajectory in the sport of archery. For more information, visit www.loxooncology.com.

Contact:
for Loxo Oncology
Paul Laland, 415-946-1071
plaland@brewlife.com


News Index

Venture Capital Database

Venture Capital Deals Spreadsheet

 

 NEWS

Latest VC News
VC News Archive
News Search
Venture Capital Deals
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

vcaDeals
Download Sample
Buy Now

VC Tools

VC Pitch
Private Placement Memorandum

Business Plan Tools

Free Business Plan Template
Business Plan Tools

 

 

Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer